Advanced Therapy Medicinal Products Market Size & Growth Forecast 2027–2036, By Segments (Therapy Type), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Advanced Therapy Medicinal Products Market size was more than USD 49.3 billion in 2026 and is set to grow at a 15.2% CAGR between 2027 and 2036, reaching USD 202.94 billion by 2036. The industry revenue for 2027 is estimated at USD 55.61 billion.
Get more details on this report
Request Free Sample ReportAdvanced Therapy Medicinal Products Market Intelligence Snapshot
Regional Market Dynamics
- North America leads with 47.17% share due to strong biopharmaceutical innovation, advanced clinical development activity, and established manufacturing and regulatory pathways enabling faster commercialization of complex therapies.
- Asia Pacific is expanding at 18.82% CAGR, driven by growing biomanufacturing capacity, rising investment in regenerative medicine, and increasing clinical adoption across advanced healthcare systems.
Segment Momentum
- Tissue Engineered Products lead the market because they address established clinical needs in tissue repair and regeneration, with applications in wound management, orthopedic repair, and reconstructive procedures supporting consistent adoption.
- Gene Therapy is the fastest-growing segment due to increasing focus on treatments that target diseases at the genetic level, particularly for inherited and complex disorders where conventional approaches offer limited benefit.
Market Expansion Drivers
- Increasing commercialization of CAR-T and gene therapies driving breakthrough treatment adoption.
- Rising clinical trials in cell and tissue engineering expanding advanced therapy pipelines.
- Growing CDMO investments enhancing large-scale manufacturing capacity for advanced therapies.
Leading Market Participants
- Major companies in the advanced therapy medicinal products market include Novartis AG (Switzerland), Spark Therapeutics, Inc. (USA), Bluebird Bio, Inc. (USA), UniQure N.V. (Netherlands), JCR Pharmaceuticals Co., Ltd. (Japan), Vericel Corporation (USA), Organogenesis Inc. (USA), Kolon TissueGene, Inc. (South Korea), MEDIPOST Co., Ltd. (South Korea), PHARMICELL Co., Ltd. (South Korea).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 49.3 billion
- 2027 Estimated Market Size: USD 55.61 billion.
- Projected Market Size: USD 202.94 billion by 2036
- Growth Forecast: 15.2% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Tissue Engineered Product (Therapy Type)
- Emerging Opportunity Segment: Gene Therapy (Therapy Type)
Market Growth Drivers and Industry Trends
Increasing commercialization of CAR-T and gene therapies driving breakthrough treatment adoption
Increasing commercialization of CAR-T and gene therapies will drive the advanced therapy medicinal products market growth by expanding access to treatments designed to address complex diseases through targeted cellular and genetic mechanisms. Greater movement from clinical development toward commercial availability supports treatment adoption while encouraging healthcare providers to build capabilities for administering and managing these therapies. The expanding use of personalized therapeutic approaches also strengthens demand for specialized treatment infrastructure, patient monitoring, and supporting services associated with advanced therapies.
Rising clinical trials in cell and tissue engineering expanding advanced therapy pipelines
The advanced therapy medicinal products market growth is being supported by rising clinical activity in cell and tissue engineering, which is broadening the range of therapeutic candidates progressing through development pipelines. Research into engineered cells and tissues can create new approaches for restoring damaged biological functions and addressing conditions where conventional treatments have limitations. As more candidates advance through clinical evaluation, the growing diversity of therapeutic applications increases development activity across specialized advanced therapy areas.
Growing CDMO investments enhancing large-scale manufacturing capacity for advanced therapies
Growing investment by contract development and manufacturing organizations will propel the advanced therapy medicinal products market growth by strengthening specialized production capabilities required for increasingly complex therapies. CDMO capacity can help developers address manufacturing challenges related to process scalability, quality control, specialized facilities, and consistent production while reducing the need to build all capabilities internally. Expanded external manufacturing infrastructure also supports developers as therapies progress from clinical stages toward broader commercial production.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Increasing commercialization of CAR-T and gene therapies driving breakthrough treatment adoption | 2.00% | High | North America, Europe | High | Near Term |
| Rising clinical trials in cell and tissue engineering expanding advanced therapy pipelines | 1.50% | High | North America, Asia Pacific | Medium | Mid Term |
| Growing CDMO investments enhancing large-scale manufacturing capacity for advanced therapies | 1.00% | Moderate | Europe, Asia Pacific | Emerging | Long Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
In the advanced therapy medicinal products market, North America accounted for the largest share of 47.17% in 2026, supported by a well-developed biotechnology ecosystem, advanced healthcare infrastructure, and strong clinical research capabilities. The region benefits from established pathways for the development and adoption of innovative therapies, while growing investment in cell and gene-based treatments strengthens demand for advanced manufacturing and specialized therapeutic capabilities. Increasing focus on personalized medicine and the treatment of complex diseases further supports North America's strong market position.
Asia Pacific (Fastest-Growing Region)
Asia Pacific represents the fastest-growing region, driven by expanding healthcare infrastructure, rising investment in biotechnology, and increasing interest in innovative treatment approaches. Improving research capabilities and greater adoption of advanced medical technologies are creating a more favorable environment for the development and commercialization of next-generation therapies. Growing healthcare needs and efforts to strengthen domestic biopharmaceutical capabilities are also supporting regional expansion.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Precision Manufacturing FocusGermany emphasizes high-quality bioprocessing infrastructure and advanced manufacturing standards for advanced therapy medicinal products. The country supports efficient technology transfer between research institutions and commercial production facilities to strengthen product development capabilities.
France 🇫🇷
Translational Research NetworkFrance supports the advanced therapy medicinal products market by connecting clinical research centers with specialized manufacturing capabilities. Continued investment in translational medicine encourages development of innovative therapies for complex disease areas.
Italy 🇮🇹
Specialized Treatment DevelopmentItaly focuses on expanding clinical expertise and specialized manufacturing capabilities for advanced therapy medicinal products. Collaboration between hospitals, research organizations, and biotechnology firms supports wider access to personalized therapeutic solutions.
Japan 🇯🇵
Regenerative Medicine AdoptionJapan advances the advanced therapy medicinal products market through supportive pathways for regenerative medicine and close integration between academic research and clinical practice. Companies continue investing in specialized manufacturing and patient-focused therapeutic applications.
South Korea 🇰🇷
Bioprocess Expansion StrategySouth Korea is strengthening advanced therapy medicinal products production through expanded biomanufacturing capacity and innovation partnerships. Local developers are focusing on scalable production platforms and internationally aligned quality systems for advanced therapies.
United States 🇺🇸
Clinical Commercialization HubThe U.S. continues to prioritize scalable manufacturing, clinical translation, and regulatory coordination for advanced therapy medicinal products. Strong collaboration among biotechnology companies, contract manufacturers, and healthcare providers supports broader adoption of complex cell and gene therapies.
Segment Leadership and Growth Trends
Advanced Therapy Medicinal Products Market Share (%), by Therapy Type, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportTherapy Type Segment Analysis: Tissue Engineered Product (Largest Segment) vs Gene Therapy (Fastest-Growing Segment)
Tissue engineered product held the largest share of the advanced therapy medicinal products market in 2026, supported by growing interest in regenerative approaches designed to restore, replace, or repair damaged tissues. Advances in cell-based technologies, biomaterials, tissue engineering, and regenerative medicine are enabling the development of therapies that address conditions where conventional treatment approaches may provide limited restoration of tissue function. Increasing research activity and clinical interest in regenerative solutions are contributing to the established position of tissue engineered products within the advanced therapy landscape.
Gene therapy is expected to be the fastest-growing segment as advances in genetic medicine are expanding opportunities to address diseases at their underlying molecular or genetic causes. Improvements in gene delivery technologies, vector engineering, and therapeutic development are increasing the potential application of gene-based interventions across a broad range of conditions. Rising investment in personalized and potentially disease-modifying treatments, together with continued progress in genetic research, is creating strong momentum for gene therapy adoption.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Therapy Type | Cell Therapy, Gene Therapy, Tissue Engineered Product | Tissue Engineered Product | Gene Therapy |
Competitive Landscape and Market Positioning
Top players in the advanced therapy medicinal products market:
1. Novartis AG (Switzerland)
2. Spark Therapeutics Inc. (USA)
3. Bluebird Bio Inc. (USA)
4. UniQure N.V. (Netherlands)
5. JCR Pharmaceuticals Co. Ltd. (Japan)
6. Vericel Corporation (USA)
7. Organogenesis Inc. (USA)
8. Kolon TissueGene Inc. (South Korea)
9. MEDIPOST Co. Ltd. (South Korea)
10. PHARMICELL Co. Ltd. (South Korea)
The advanced therapy medicinal products market is expanding through increased focus on gene therapies, regenerative medicine, and cell-based treatment platforms. Research initiatives targeting rare and complex diseases are encouraging innovation in manufacturing scalability and therapeutic delivery methods. Growing collaboration across biotechnology ecosystems is also accelerating commercialization activities in the advanced therapy medicinal products market.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Novartis AG (Switzerland) | |||||||
| Spark Therapeutics Inc. (USA) | |||||||
| Bluebird Bio Inc. (USA) | |||||||
| UniQure N.V. (Netherlands) | |||||||
| JCR Pharmaceuticals Co. Ltd. (Japan) | |||||||
| Vericel Corporation (USA) | |||||||
| Organogenesis Inc. (USA) | |||||||
| Kolon TissueGene Inc. (South Korea) | |||||||
| MEDIPOST Co. Ltd. (South Korea) | |||||||
| PHARMICELL Co. Ltd. (South Korea). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Scinai Immunotherapeutics | May-26 | Scinai Immunotherapeutics acquired Recipharm Israel Ltd. and entered a commercial partnership with Recipharm to augment its capabilities in inflammation and immunology-focused biotherapeutics. This transaction significantly enhances Scinai’s manufacturing and commercialization infrastructure, providing greater operational scale for its participation in the broader cell and gene therapy ecosystem. |
| Neuland Laboratories | May-26 | Neuland Laboratories partnered with LIR Life Sciences to advance a cell-penetrating peptide platform designed for transdermal GLP-1 delivery. This collaboration integrates novel patch-based peptide delivery technologies into the company's development pipeline, strengthening its technical capabilities in addressing therapeutic delivery challenges within advanced cell and gene therapy modalities. |
| Porton Advanced | May-26 | Porton Advanced and Dark Horse Consulting Group entered a memorandum of understanding to streamline the clinical translation of cell and gene therapies. The collaboration leverages integrated consulting and CDMO capabilities to optimize investigational new therapy pathways in China, enhancing service delivery for developers seeking to navigate complex ATMP regulatory and development frameworks. |
| Iran’s Royan Research Institute | Feb-26 | Iran’s Royan Research Institute announced the development of six domestic cell therapy and tissue engineering products, contributing to a national pipeline of approximately 110 advanced therapy medicinal products. This initiative marks a strategic increase in national manufacturing capacity, positioning the institution as a significant developer within the regional regenerative medicine landscape. |
| Recipharm | Oct-25 | Recipharm designated its Germany site as a Centre of Excellence for ATMP manufacturing following a comprehensive facility renovation. This strategic upgrade enhances the company’s capacity for multi-product GMP production, allowing for more robust support of cell and gene therapy development and commercial manufacturing within the European market. |
| BIH at Charité & ProBioGen | Sep-25 | The Berlin Institute of Health at Charité and ProBioGen established the Berlin Center for Gene and Cell Therapies, featuring a 4,600 m² GMP facility. Supported by €76.5 million in federal funding, this infrastructure project is designed to accelerate the translation of gene and cell therapy research into clinical applications through enhanced manufacturing capacity. |
| Admaius Capital & Minapharm | Jul-25 | Admaius Capital and Minapharm initiated a strategic partnership to strengthen the African biopharma ecosystem by scaling cell and gene therapy capabilities. The collaboration focuses on enhancing regional biotech innovation, infrastructure, and manufacturing capacity, aimed at improving local access to the development and production of advanced therapy medicinal products. |
| BIH at Charité & BioLabs | May-25 | The Berlin Institute of Health at Charité partnered with BioLabs to launch a clinical incubator (CLIC) dedicated to ATMP development. By providing shared infrastructure and specialized support services, the initiative is designed to shorten the transition period for regenerative medicine research, facilitating the progression of clinical-stage therapies toward commercialization. |
| UZ Leuven & KU Leuven | Oct-24 | UZ Leuven and KU Leuven invested €14 million to construct a specialized facility for the production of advanced therapy medicinal products at the Gasthuisberg Campus. This investment is intended to bolster regional capacity for developing and manufacturing personalized cell and gene therapies, directly facilitating the clinical translation of novel regenerative medicine treatments. |
| Seqens | Apr-24 | Seqens diversified its CDMO service portfolio by acquiring CELLforCURE, marking its formal entry into the cell and gene therapy manufacturing market. This strategic acquisition expands the company’s technical capabilities from small-molecule production into complex ATMP manufacturing, strengthening its competitive positioning within the rapidly evolving biologics and cell-based therapeutic service landscape. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Advanced Therapy Medicinal Products Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Therapeutic Area | Oncology, Rare Diseases, Neurological Disorders, Hematological Disorders, Autoimmune and Inflammatory Diseases, Other Therapeutic Areas |
| Development Stage | Preclinical, Phase I, Phase II, Phase III, Regulatory Review, Commercialized |
| Manufacturing Model | In-House Manufacturing, Contract Manufacturing, Hybrid Manufacturing |
Advanced Therapy Medicinal Products Market — Custom
| Custom Chapter | Custom Details |
|---|---|
| Commercialization Readiness Assessment |
|
| Manufacturing Capacity and CDMO Landscape |
|
| Reimbursement and Market Access Outlook |
|
Need a different cut of the data?
Request Custom ResearchHow much is the advanced therapy medicinal products market worth?
How is the advanced therapy medicinal products industry expected to grow over the next 10 years?
How is the commercialization of CAR-T and gene therapies reshaping demand in the advanced therapy medicinal products market?
Why are manufacturing investments by CDMOs becoming strategically important in the advanced therapy medicinal products market?
Why do Tissue Engineered Products hold the largest share of the advanced therapy medicinal products market?
Which therapy type is growing fastest in the advanced therapy medicinal products market?
Why does North America lead the advanced therapy medicinal products market?
What is driving Asia Pacific growth in the ATMP market?
What are the key competitors in the advanced therapy medicinal products landscape?
Our Clients
"The reports offered a comprehensive view of the Food and Beverage landscape, covering market trends, consumer behavior, and competitive dynamics."
"Our experience in acquiring market research reports has been outstanding — the depth of analysis and actionable insights have proven invaluable."
"Fundamental Business Insights demonstrated a keen understanding of our business needs, delivering reports tailored to our specific objectives."
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization